Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy.
Nigel McCracken, Virax COO, Discusses the New Frontier in Immune Diagnostics with The Scientist in This Innovation Spotlight.
Virax COO, Nigel McCracken, Exaplains the Latest PAIS IVD Technolgy in His Latest PharmExec.com Interview.
In His Latest PharmExec.com Interview, Virax COO Nigel McCracken Shares New Insights Into the Link Between T Cell Exhaustion and Inflammation in Long-COVID.
Virax COO, Nigel McCracken, Discusses New Data on T Cell Exhaustion in Post-Acute Infection Syndromes with PharmExec.com in Latest Article.
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
Virax Biolabs Presentation from the 19th World Immune Regulation Meeting: “Evaluation of T cell dysfunction in Post Acute Infection Syndromes”
Dr. Nigel McCracken, our Chief Operating Officer, will present on “Evaluation of T cell dysfunction in Post Acute Infection Syndromes” at the 19th World Immune Regulation Meeting (WIRM) in Davos, Switzerland today (March 12th) at 8pm in Foyer A1. For those not able to join us in Davos, you can have a look at the poster here or use the link below to download a copy for a closer look:
Virax Biolabs to Present at 19th World Immune Regulation Meeting
Tune in now to listen to Dr. Nigel McCracken talk about “The Power of T Cell Immunology: Early Diagnosis, Immunotherapy, & the Future of Global Health” on the Finding Genius podcast
